An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
← catalyst calendarNCT04740476 · readout in 955 d
Sponsored by Stoke Therapeutics, Inc (industry) · STOK — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-20 | actual | When the study began enrolling |
| Primary completion | 2029-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dravet Syndrome
Intervention
- Drug: zorevunersen (STK-001)
Primary outcome
what the primary-completion date above is the date OFSafety of multiple doses of zorevunersen
measured Screening (Day -1) until 6 months after multiple drug dosing
Publications
- PMID 41780062 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · STOK's whole pipeline · Catalyst calendar · Every registered study · What changed